Drug intelligence / Profile preview

NCE-03

Development stage: Preclinical
Lead developer: MetaFines
Modality: Small Molecules

Overview

NCE-03 is a small molecule therapeutic candidate currently in preclinical development by MetaFines. It is specifically being investigated for the management of obesity, with a focus on preventing rebound weight gain (weight maintenance) following the use of GLP-1 receptor agonists. The compound is intended to be used as a combination therapy alongside GLP-1 agents to improve the long-term efficacy and durability of weight loss interventions. NCE-03 is part of MetaFines' pipeline targeting metabolic disorders through their proprietary metabolic fine-tuning approach.

Beyond the preview

Go deeper on NCE-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCE-03.

Explore the full profile